Effect of Catheter Ablation for Atrial Fibrillation in Heart Failure With Mid-Range or Preserved Ejection Fraction ― Pooled Analysis of the AF Frontier Ablation Registry and Hokuriku-Plus AF Registry ―
Toyonobu Tsuda, Takeshi Kato, Keisuke Usuda, Takashi Kusayama, Soichiro Usui, Kenji Sakata, Kenshi Hayashi, Masa‐aki Kawashiri, Masakazu Yamagishi, Masayuki Takamura, Takayuki Otsuka, Shinya Suzuki, Akio Hirata, Masato Murakami, Mitsuru Takami, Masaomi Kimura, Hidehira Fukaya, Shiro Nakahara, Wataru Shimizu, Yu‐ki Iwasaki, Hiroshi Hayashi, Tomoo Harada, Ikutaro Nakajima, Ken Okumura, Junjiroh Koyama, Michifumi Tokuda, Teiichi Yamane, Yukihiko Momiyama, Kojiro Tanimoto, Kyoko Soejima, Noriko Nonoguchi, Koichiro Ejima, Nobuhisa Hagiwara, Masafumi Harada, Kazumasa Sonoda, Masaru Inoue, Koji Kumagai, Hidemori Hayashi, Kazuhiro Satomi, Yoshinao Yazaki, Yuji Watari, Masaru Arai, Ryuta Watanabe, Katsuaki Yokoyama, Naoya Matsumoto, Koichi Nagashima, Yasuo Okumura, on behalf of the AF Ablation Frontier Registry and the Hokuriku-Plus AF Registry Investigators
Abstract
BACKGROUND: A recent randomized trial demonstrated that catheter ablation for atrial fibrillation (AF) in patients with heart failure with reduced ejection fraction (EF) is associated with a reduction in death or heart failure. However, the effect of catheter ablation for AF in patients with heart failure with mid-range or preserved EF is unclear. METHODS AND RESULTS: We screened 899 AF patients (72.4% male, mean age 68.4 years) with heart failure and left ventricular EF ≥40% from 2 Japanese multicenter AF registries: the Atrial Fibrillation registry to Follow the long-teRm Outcomes and use of aNTIcoagulants aftER Ablation (AF Frontier Ablation Registry) as the ablation group (525 patients who underwent ablation) and the Hokuriku-Plus AF Registry as the medical therapy group (374 patients who did not undergo ablation). Propensity score matching was performed in these 2 registries to yield 106 matched patient pairs. The primary endpoint was a composite of cardiovascular death and hospitalization for heart failure. At 24.6 months, the ablation group had a significantly lower incidence of the primary endpoint (hazard ratio 0.32; 95% confidence interval 0.13-0.70; P=0.004) than the medical therapy group. CONCLUSIONS: Compared with medical therapy, catheter ablation for AF in patients with heart failure and mid-range or preserved EF was associated with a significantly lower incidence of cardiovascular death or hospitalization for heart failure.